Unicycive reports $61.4M cash balance in Q2 update
Unicycive Therapeutics, Inc. reported an ending cash balance of approximately $61.4 million as of June 30, 2026.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Unicycive Therapeutics, Inc. reported an ending cash balance of approximately $61.4 million as of June 30, 2026. This figure is part of the company’s preliminary second-quarter results, which were prepared by management and have not been audited, reviewed, or compiled by its independent registered public accounting firm.
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
Ending cash balance: $61.4 million
1 metrics
Ending cash balance
$61.4 million
As of June 30, 2026; preliminary and unaudited
Key Terms
Form 8-K, Item 8.01 Other Events, preliminary results, independent registered public accounting firm, +1 more
5 terms
Form 8-K regulatory
"FORM 8-K Pursuant to Section 13 or 15(d) of the Securities Exchange Act"
A Form 8-K is a report that companies file with the government to share important news quickly, such as changes in leadership, major business deals, or financial updates. It matters because it helps investors stay informed about significant events that could affect the company's value or stock price.
Item 8.01 Other Events regulatory
"Item 8.01 Other Events. The Company had an ending cash balance"
preliminary results financial
"The preliminary results for the second quarter ended June 30, 2026, have been prepared"
Initial, incomplete findings released early from a study, clinical trial, financial audit, or other investigation before the full data set and final analysis are complete. They matter to investors because they offer an early signal about a project’s direction—like a first draft of results—but can change as more data is collected, verified, or analyzed, so they carry higher uncertainty than final, peer-reviewed or audited outcomes.
independent registered public accounting firm regulatory
"Neither our independent registered public accounting firm, nor any other independent accountants, have audited"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What cash balance did Unicycive Therapeutics (UNCY) report as of June 30, 2026?
Unicycive Therapeutics reported an ending cash balance of approximately $61.4 million as of June 30, 2026. This amount is part of the company’s preliminary second-quarter results and reflects the cash available on its balance sheet at that date.
Are Unicycive Therapeutics’ Q2 2026 results audited or reviewed by accountants?
The preliminary second-quarter 2026 results for Unicycive Therapeutics have not been audited, reviewed, compiled, or subjected to procedures by its independent registered public accounting firm. Management prepared these figures, and no external assurance or opinion has been provided on the results.
What SEC form did Unicycive Therapeutics (UNCY) file for this cash update?
Unicycive Therapeutics submitted a Form 8-K under Item 8.01 Other Events to disclose its preliminary cash balance. This form reports significant corporate developments that shareholders may find relevant, outside of regular quarterly or annual financial statements.
Why did Unicycive Therapeutics disclose its cash balance in a Form 8-K?
The company used a Form 8-K to highlight its approximate $61.4 million cash balance as of June 30, 2026. Filing under Item 8.01 lets Unicycive provide timely information on liquidity that may be important for investors evaluating its financial position.
Who signed the July 2, 2026 Unicycive Therapeutics Form 8-K filing?
The Form 8-K dated July 2, 2026 was signed on behalf of Unicycive Therapeutics by Shalabh Gupta, the company’s Chief Executive Officer. This signature indicates the filing was authorized by senior management in accordance with SEC requirements.
AI-generated analysis. How Rhea-AI works. Not financial advice.
